Business
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101
Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that new data from our ongoing ATALANTA-1 Phase 1/2 study of GLPG5101 in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) have been accepted for oral presentations at the 2025 European Hematology Association (EHA) Congress taking place June 12-15, 2025, in Milan, Italy, and the
About this update from Lakefront Biotherapeutics
[{"type":"image","alt":"Galapagos NV","displaySize":"","headline":null,"caption":"Galapagos NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/231a79f212c8051361274fdd509bada9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/n2iAy9u_uXZxYevnIzv00A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/231a79f212c8051361274fdd509bada9","width":300,"height":55}},"lazy":false},{"type":"text","content":"Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that new data from our ongoing ATALANTA-1 Phase 1/2 study of GLPG5101 in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) have been accepted for oral presentations at the 2025 European Hematology Association (EHA) Congress taking place June 12-15, 2025, in Milan, Italy, and the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland the following week.","length":601,"tagName":"p"},{"type":"text","content":"“At Galapagos, we are driven by a mission to expand access to transformative cell therapies for patients facing serious hematological and solid tumors, where unmet needs remain high,” said Omotayo Fasan, M.D., Clinical Development Program Head at Galapagos. “We are excited to present new data for GLPG5101 in multiple relapsed/refractory non-Hodgkin lymphoma subtypes, which continue to support our approach of rapidly delivering fresh, stem-like early memory cells to potentially improve outcomes.”","length":500,"tagName":"p"},{"type":"text","content":"The data to be presented are summarized below:","length":46,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The oral presentation at EHA will feature new safety and longer follow-up data for GLPG5101 in 64 patients with R/R large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and marginal zone lymphoma (MZL) from the ongoing ATALANTA-1 Phase 1/2 study.","length":278,"tagName":"p"}]},{"val":[{"type":"text","content":"The oral presentation at ICML will feature new and full results from ATALANTA-1 Cohort 3 (indolent NHL, iNHL) on safety, efficacy and translational data for GLPG5101 ...